Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera

Core Viewpoint - The proposed merger of two weight-loss drugmakers is facing a lawsuit that claims it could eliminate a smaller competitor in the market [1] Group 1 - The lawsuit argues that the merger would significantly reduce competition in the weight-loss drug industry [1] - Concerns have been raised that the merger could lead to higher prices and fewer choices for consumers [1] - The smaller competitor, which is not named in the lawsuit, is said to be at risk of being driven out of the market if the merger proceeds [1]